Ì points to considerî regarding safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies (English translation)

12Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Regulatory and industrial scientists collaborated to publish a ì points to considerî document regarding the safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies in 2002 (Pharmaceutical Non-clinical Investigation Group, 2002). The collaboration team intended to clarify the interpretation of ICH-S6 guideline and furthermore share recent Japanese practices on this matter. However, the document was written in Japanese. Thus, we share here an English translation of the document so that non-native Japanese correctly understand the contents.

Cite

CITATION STYLE

APA

Nakazawa, T., Kai, S., Kawai, M., Maki, E., Sagami, F., Onodera, H., … Inoue, T. (2004). Ì points to considerî regarding safety assessment of biotechnology-derived pharmaceuticals in non-clinical studies (English translation). Journal of Toxicological Sciences. Japanese Society of Toxicology. https://doi.org/10.2131/jts.29.497

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free